6 Clopidogrel remains the most prescribed P2Y12 inhibitor world-wide due to significantly lower cost than ticagrelor and prasugrel, and therefore the impact of vulnerability to clopidogrel nonresponse is extremely significant particularly in populations with high prevalence of CYP2C19 loss-of-function variants in the context of secondary prevention after myocardial infarction.
← all excerpts
Clopidogrel Pharmacogenomics: Validation in a Population of South-Asian Ancestry.
1
—
—